Frontiers in the COVID-19 vaccines development

Frontiers in the COVID-19 vaccines development

Jifeng Yu, Ehtisham Ul Haq, Jiancheng Guo

Abstract Novel corona virus caused pneumonia first reported in December, 2019 in Wuhan, China was later named COVID-19. Due to its special pathogenicity, COVID-19 transmitted with high speed beyond borders and has significantly affected normal life. Currently, no specific drugs, treatment or vaccines are available. Vaccine development for COVID-19 is a highly complex process involving viral genomic studies, identification of target for vaccine, vaccine design, manufacturing, storage and distribution, preclinical and clinical safety and efficacy studies. The high levels of efforts and global collaboration at this scale is unprecedented. The World Health Organization (WHO) has documented 160 different COVID-19 vaccine candidates as of July 13, 2020 with 26 currently on clinical evaluation while 137 vaccines on preclinical evaluation. COVID-19 vaccine efforts mark the first use of mRNA-type vaccines ever evaluated. Numerous research organizations have successfully initiated clinical evaluation of COVID-19 vaccines. This review aims to summarize the advances and challenges for COVID-19 vaccines development.

2020

vaccine development, covid-19, RNA and DNA vaccine

10.1186/s40164-020-00180-4

Biotemas

Universidade Federal de Santa Catarina

Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Diseases of the blood and blood-forming organs